Annual report
4005.TEDINET S100VXZW
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.61T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.90T | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.77T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.29T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥193.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥488.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥58.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥231m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥251.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥137.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥38.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥162.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥46.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥42.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥46.9bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥186.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥68.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥3.44T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.93T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.17T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥4.31T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.99T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.37T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.07T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥900.8bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.22T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.02T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥209.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥365.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥360.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥233.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥111.6bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥171.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥374.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥85.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥19.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥115.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥177.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥300.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥178.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥81.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥23.59 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥4.27 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥99.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥28.16 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥23.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥4.27 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥550.37 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥590.44 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥716.26 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥745.03 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥623.39 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.1% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.3% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.5% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 4.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -29.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 0.6% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 29,279 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 32,161 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 33,572 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 34,703 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 34,743 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥856.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥809.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥894.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥797.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥646.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥59.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥84.9bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥53.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥69.5bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥68.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥38.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥42.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥10.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥24.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥50.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥61.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥41.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.82T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.90T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.77T | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.74T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.73T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.42T | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.53T | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥393.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥370.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥378.0bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥368.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥346.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥85.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥69.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥14.77 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.32 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.85 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.76 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.52 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥9 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥18 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥240.68 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.14 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.56 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥211.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 21.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,657,217,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,656,449,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,860,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6,669 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 6,706 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6,637 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 6,488 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 6,277 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 104
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 1344 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥165.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥99.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥65.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥284.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥66.9bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥102.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥32.7bn |
| Advanced Medical Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| Advanced Medical Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥72.5bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥62.1bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.4bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2025-03-31 | ¥125.3bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Agro And Life Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥20.1bn |
| Agro And Life Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥541.3bn |
| Agro And Life Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥540.2bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2025-03-31 | ¥771.3bn |
| Agro And Life Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥55.0bn |
| Energy And Functional Materialsreportable segment | employees | at 2025-03-31 | 9620 pure |
| Essential And Green Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥26.3bn |
| Essential And Green Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥903.9bn |
| Essential And Green Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥899.0bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥4.9bn |
| Essential And Green Materialsreportable segment | segment assets | at 2025-03-31 | ¥791.9bn |
| Essential And Green Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥58.5bn |
| Essential Chemicals And Plasticsreportable segment | employees | at 2025-03-31 | 7366 pure |
| Health And Agriculture Relatedreportable segment | employees | at 2025-03-31 | 3609 pure |
| ICT And Mobility Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥49.2bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥610.3bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥607.0bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.3bn |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2025-03-31 | ¥635.7bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥70.6bn |
| Information Electronic Chemistryreportable segment | employees | at 2025-03-31 | 2115 pure |
| Medical Productsreportable segment | employees | at 2025-03-31 | 3828 pure |
| Sumitomo Pharmareportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Sumitomo Pharmareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥398.5bn |
| Sumitomo Pharmareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥398.0bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥529m |
| Sumitomo Pharmareportable segment | segment assets | at 2025-03-31 | ¥728.7bn |
| Sumitomo Pharmareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥35.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥120.1bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.53T |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.51T |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥20.2bn |
| —segment total | segment assets | at 2025-03-31 | ¥3.05T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥106.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥162.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥85.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥76.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥426.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥11.6bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥9.4bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥102.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥102.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥45.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥27.6bn |
| Advanced Medical Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥7.9bn |
| Advanced Medical Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥73.4bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥58.5bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥14.9bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2024-03-31 | ¥118.4bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.1bn |
| Agro And Life Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥27.8bn |
| Agro And Life Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥517.6bn |
| Agro And Life Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥515.6bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2024-03-31 | ¥842.8bn |
| Agro And Life Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Essential And Green Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥29.2bn |
| Essential And Green Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥891.0bn |
| Essential And Green Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥885.9bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Essential And Green Materialsreportable segment | segment assets | at 2024-03-31 | ¥953.4bn |
| Essential And Green Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥89.1bn |
| ICT And Mobility Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥61.9bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥591.1bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥587.4bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2024-03-31 | ¥649.6bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥50.0bn |
| Sumitomo Pharmareportable segment | capex | 2023-04-01 → 2024-03-31 | ¥16.3bn |
| Sumitomo Pharmareportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥313.9bn |
| Sumitomo Pharmareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥313.8bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥95m |
| Sumitomo Pharmareportable segment | segment assets | at 2024-03-31 | ¥899.6bn |
| Sumitomo Pharmareportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥126.4bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥143.1bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.39T |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.36T |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥25.8bn |
| —segment total | segment assets | at 2024-03-31 | ¥3.46T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥133.1bn |
| Energy And Functional Materialsreportable segment | employees | at 2025-03-31 | 1847 pure |
| Essential Chemicals And Plasticsreportable segment | employees | at 2025-03-31 | 1470 pure |
| Health And Agriculture Relatedreportable segment | employees | at 2025-03-31 | 1513 pure |
| Information Electronic Chemistryreportable segment | employees | at 2025-03-31 | 600 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,606
| Item | Context | Value | Unit |
|---|---|---|---|
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 16.3 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8183357 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 1470 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 80 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 1847 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 146 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000InformationElectronicChemistryReportableSegmentMember | 600 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 54 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 1513 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 70 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1239 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 84 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 6669 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 434 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.091 | |
| All employees calculated based on provisions of article714 item2 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 1.094 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.764 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.772 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.710 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.026 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.857 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.606 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.743 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.596 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.085 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 1.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.795 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.807 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.464 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.000 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.250 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.654 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.659 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.745 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.238 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 1.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.670 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.787 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.754 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.000 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.800 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.502 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.703 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.405 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | 0.204 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | 0.846 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | 0.765 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | 0.842 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | 0.533 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | 0.000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |